Literature DB >> 16685488

[Mesenchymal stem cells from bone marrow. Phenotype, aspects of biology, and clinical perspectives].

Gerald G Wulf1, Björn Chapuy, Lorenz Trümper.   

Abstract

BACKGROUND: Since their initial description by Friedenstein et al. 30 years ago, mesenchymal stem cells have been characterized as a cell population of the bone marrow, which is easily accessible and readily manageable for in vitro manipulation.
RESULTS: Cell biology studies have delineated the phenotype of mesenchymal stem cells, optimized the conditions for in vitro expansion, and documented their differentiation capacity along mesodermal lineages. First clinical applications as an adjunct to stem cell transplantation regimens have shown some potential in osteogenic regeneration as well as immunosuppressive effects after allogeneic stem cell transplantation. Animal studies have further shown, that mesenchymal stem cells may serve as vehicles for the transfer of genetic material. Preclinical studies remain, however, to answer numerous questions with regard to populational heterogeneity and the physiological roles of this cell compartment.
CONCLUSION: Further preclinical studies as well as clinical cell therapy studies are essential to fully exploit the potential of mesenchymal stem cells in regenerative medicine, cellular immunotherapy, and gene therapy.

Mesh:

Year:  2006        PMID: 16685488     DOI: 10.1007/s00063-006-1052-6

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  2 in total

1.  In vitro induction and differentiation of umbilical cord mesenchymal stem cells into neuron-like cells by all-trans retinoic acid.

Authors:  Wei Jin; Yao-Peng Xu; An-Huai Yang; Yi-Qiao Xing
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

2.  Human adipose derived stem cells induced cell apoptosis and s phase arrest in bladder tumor.

Authors:  Xi Yu; Boxing Su; Peng Ge; Zicheng Wang; Sen Li; Bingwei Huang; Yanqing Gong; Jian Lin
Journal:  Stem Cells Int       Date:  2015-01-27       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.